SNY vs. VRTX, BMY, REGN, PFE, GSK, ZTS, ABT, NVS, TAK, and BIIB
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Pfizer (PFE), GSK (GSK), Zoetis (ZTS), Abbott Laboratories (ABT), Novartis (NVS), Takeda Pharmaceutical (TAK), and Biogen (BIIB). These companies are all part of the "medical" sector.
Sanofi (NASDAQ:SNY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.
In the previous week, Vertex Pharmaceuticals had 21 more articles in the media than Sanofi. MarketBeat recorded 39 mentions for Vertex Pharmaceuticals and 18 mentions for Sanofi. Vertex Pharmaceuticals' average media sentiment score of 0.59 beat Sanofi's score of 0.23 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Sanofi has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.
Sanofi currently has a consensus target price of $55.00, indicating a potential upside of 18.00%. Vertex Pharmaceuticals has a consensus target price of $429.45, indicating a potential upside of 7.16%. Given Sanofi's higher possible upside, analysts plainly believe Sanofi is more favorable than Vertex Pharmaceuticals.
Vertex Pharmaceuticals received 1514 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 53.23% of users gave Sanofi an outperform vote.
Sanofi has higher revenue and earnings than Vertex Pharmaceuticals. Sanofi is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Sanofi's net margin of 12.56%. Sanofi's return on equity of 27.47% beat Vertex Pharmaceuticals' return on equity.
10.0% of Sanofi shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Vertex Pharmaceuticals beats Sanofi on 12 of the 18 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
